(Press-News.org) DURHAM, N.C.— An ambitious effort to coordinate heart attack care among every hospital and emergency service in North Carolina improved patient survival rates and reduced the time from diagnosis to treatment, according to Duke University Medical Center researchers who spearheaded the program.
"When treating heart attacks, the most important care decisions need to take place before the patient is brought to the hospital," says James Jollis, M.D., a Duke cardiologist and first author of the findings published today in the journal Circulation. "These procedures should be in place in every hospital and every emergency service system in the country."
RACE-ER (Reperfusion of Acute Myocardial Infarction in Carolina Emergency Departments – Emergency Response) is the largest voluntary statewide heart attack care intervention ever undertaken in the United States. Thousands of health care professionals from North Carolina's 119 hospitals collaborated with more than 500 emergency service agencies across 53,000 square miles. RACE-ER is an extension of an earlier pilot program that covered five North Carolina regions and brought together 10 PCI centers and 55 hospitals in 2007.
From July 2008 through December 2009, RACE-ER decreased the time from first contact to medical treatment from 103 minutes to 91 minutes when patients were brought directly to hospitals that performed angioplasty, now known as percutaneous coronary intervention (PCI). Of those patients, 52% were treated within 60 minutes.
Treatment times for patients transferred from non-PCI hospitals to PCI centers improved from 117 minutes to 103 minutes. Thirty-nine percent of transferred patients were treated within 90 minutes by December 2009.
"Our intervention demonstrates how competing healthcare entities can work together to overcome the systematic barriers that prevent timely heart attack treatment," says Jollis. "We were able to embed a standard of care that was independent of what hospital the patient was brought to or where the heart attack occurred. By the end of our intervention, our protocols were adopted by state regulation for all EMS agencies, and all hospitals agreed to continue supporting regional care."
RACE-ER focused on treatment of the most deadly form of heart attack known as STEMI (ST Segment Elevation Myocardial Infarction), which occurs when a sudden blockage in a coronary artery damages the heart muscle. Each year, about 300,000 people have a STEMI, according to the American Heart Association. National guidelines call for blocked arteries to be opened medically or surgically within 90 minutes of a patient's first contact with the emergency medical system, either paramedic arrival, or arrival of self-transported patients at the hospital door.
"Every second counts when it comes to salvaging the heart muscle and saving lives," says Christopher Granger, M.D., a Duke cardiologist and co-author of the study. "This statewide effort was designed to treat patients faster regardless of the challenges posted by geography or healthcare settings. We coordinated a system of care that starts when the 911 call comes in, includes the care patients receive in the ambulance, and the treatment they undergo at hospitals to restore blood flow in blocked heart arteries. As a result, when patients were treated within the 90-minute door-to-device goal, we were able to reduce mortality rates to 2.2 percent." By comparison, the mortality rates stands at 5.7 percent when door-to-device treatment exceeds the 90-minute goal.
RACE-ER also emphasizes the need for paramedics to diagnose heart attacks in the field using ECGs, which can provide necessary information to mobilize interventional cardiology teams. The North Carolina researchers showed that pre-hospital ECG rates for patients transported to PCI hospitals by emergency medical services (EMS) increased from 67 percent to 88 percent.
Using this approach, patients are transported directly to waiting catheterization laboratories. Prior evidence shows paramedics can reliably diagnose heart attacks, and more than half of patients are treated within 60 minutes of hospital arrival.
Duke is now working with the American Heart Association to implement programs similar to RACE-ER in 20 regions across the country including New York City, Philadelphia, Detroit, San Antonio and Phoenix.
During the next two years, the Regional Systems of Care Demonstration Project – Mission: Lifeline® STEMI Systems Accelerator program will bring together cardiologists, emergency medicine physicians, administrators, nurses, and paramedics from each region to help them implement coordinated programs specific to their needs.
Data will be collected so each region can measure their success.
###
Co-authors are Hussein R. Al-Khalidi, Ph.D.; Lisa Monk, R.N., M.S.N.; Mayme L. Roettig, R.N., M.S.N.; J. Lee Garvey, M.D.; Akinyele O. Aluko, M.D.; B. Hadley Wilson, M.D.; Robert J.Applegate, M.D.; Greg Mears, M.D.; Claire C. Corbett, M.M.S.; and Christopher B. Granger, M.D. Author disclosures are on the manuscript.
END
CHICAGO – An observational study that examined the comparative effectiveness of rhythm control vs. rate control drug treatment on mortality in patients with atrial fibrillation (a rapid, irregular heart beat) suggests there was little difference in mortality within four years of treatment, but rhythm control may be associated with more effective long-term outcomes, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
AF affects approximately 2.3 million Americans and 250,000 Canadians, and the condition has a complex ...
Family members of children with a staph infection often harbor a drug-resistant form of the germ, although they don't show symptoms, a team of researchers from Washington University School of Medicine in St. Louis has found.
The results are published in the June issue of Archives of Pediatrics & Adolescent Medicine.
The investigators focused on family members of nearly 200 children who had Staphylococcus aureus infections in the skin and soft tissue, in areas such as the nose, armpits and/or groin. They found that of the more than 600 household members who lived with ...
BOSTON -- June 4, 2012 -- Researchers at Joslin Diabetes Center have shown that while a type of "good" fat found in the body can be activated by cold temperatures, it is not able to be activated by the drug ephedrine.
The finding, published in today's issue of PNAS USA Early Edition, may lead to drugs or other methods aimed at activating the good fat, known as brown fat. When activated, brown fat burns calories and can help in the battle against obesity.
"We propose that agents that work similarly to cold in activating brown fat specifically can provide promising approaches ...
Analyzing medical records from thousands of patients, statisticians have devised a statistical model for predicting what other medical problems a patient might encounter.
Like how Netflix recommends movies and TV shows or how Amazon.com suggests products to buy, the algorithm makes predictions based on what a patient has already experienced as well as the experiences of other patients showing a similar medical history.
"This provides physicians with insights on what might be coming next for a patient, based on experiences of other patients. It also gives a predication ...
PASADENA, Calif.—A nuzzle of the neck, a stroke of the wrist, a brush of the knee—these caresses often signal a loving touch, but can also feel highly aversive, depending on who is delivering the touch, and to whom. Interested in how the brain makes connections between touch and emotion, neuroscientists at the California Institute of Technology (Caltech) have discovered that the association begins in the brain's primary somatosensory cortex, a region that, until now, was thought only to respond to basic touch, not to its emotional quality.
The new finding is described ...
A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA.
The researchers, led by Andrzej J. Jakubowiak, M.D., Ph.D., professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center, found that combining carfilzomib, a next generation proteasome inhibitor, ...
VIDEO:
As a retrovirus matures, the two parts of its shell protein (red and blue or yellow and blue) dramatically rearrange themselves, twisting and moving away from each other.
Click here for more information.
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have for the first time uncovered the detailed structure of the shell that surrounds the genetic material of retroviruses, such as HIV, at a crucial and potentially vulnerable stage ...
VIDEO:
A fruit fly embryo from when it was about two-and-a-half hours old until it walked away from the microscope as a larva, filmed by a new microscope developed at EMBL....
Click here for more information.
"This video shows a fruit fly embryo from when it was about two-and-a-half hours old until it walked away from the microscope as a larva, 20 hours later," says Lars Hufnagel, from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. "It shows all ...
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have conducted the first comprehensive census of human cells' export workers. In a study published online today in Nature Cell Biology, they found an unexpected variety of genes involved in transporting molecules to the cell membrane and beyond.
Using a combination of genetics and sophisticated microscopy, Rainer Pepperkok and colleagues systematically silenced each of our 22 000 genes, and observed to what extent this affected the cell's ability to transport a protein. They found that ...
Among the founding fathers of the biotechnology industry, Roberto Crea, PhD., founder and CEO of CreAgri Inc., is internationally acknowledged for the role he played in the successful establishment and growth of Genentech, Inc.--as one of the first four scientific founders of the legendary biotech company—and for his pioneering role in the production of many rDNA protein drugs from bacteria. Among other innovations, Dr. Crea is the inventor of the synthetic DNA process that led to the discovery of the first recombinant human insulin, Humulin , and many other pharmaceutical ...
